Quick Answer
Protagonist Therapeutics, Inc reported Operating Income Loss of -$158.13 million for the year ending 2025.
- Protagonist Therapeutics, Inc showed a decrease of -162.5% in Operating Income Loss from 2024 to 2025.
- This data is from Protagonist Therapeutics, Inc's annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), Protagonist Therapeutics, Inc's Operating Income Loss has declined by 1,596.8%.
- Historical annual values: Fiscal year 2025: -$158.13 million | Fiscal year 2024: $252.84 million | Fiscal year 2023: -$93.65 million | Fiscal year 2022: -$131.37 million | Fiscal year 2021: -$125.85 million | Fiscal year 2020: -$64.52 million | Fiscal year 2019: -$80.52 million | Fiscal year 2018: -$42.27 million | Fiscal year 2017: -$37.90 million | Fiscal year 2016: -$32.67 million | Fiscal year 2015: -$14.79 million | Fiscal year 2014: -$9.32 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: